On January 10, 2023, QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) announced that it has completed the acquisition of Verogen, a leader in the use of next-generation sequencing (NGS) technologies to drive the future of human identification (HID) and forensic investigation. Verogen, a privately held company founded in 2017 and based in San Diego, supports the global human identification community with NGS tools and professional services to help resolve criminal and missing-persons cases. QIAGEN and Verogen have been commercialization partners since announcing a distribution agreement in June 2021. QIAGEN--which in the late 1990s launched the first commercial kits to purify DNA from forensic casework samples--already has a leading position in the HID / forensics market. QIAGEN’s sample collection and preparation kits, genetic testing analysis, and workflow automation products are used around the world by forensic science laboratories and criminal investigators.